推薦產(chǎn)品
3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole 2-(chloromethyl)-3-methylpyridinehydrochloride 1-(2-bromo-4-methylphenyl)ethanone 3-chloroisoquinoline-4-carbonitrile 5,8-dichloropyrido[3,2-d]pyridazine 2-bromomalononitrile 2-(4-(bromomethyl)phenyl)benzo[d]thiazole 1-(bromomethyl)-3-methoxy-2-nitrobenzene 6-bromo-1H-[1,2,3]triazolo[4,5-b]pyridine 4-iodo-2-((trimethylsilyloxy)methyl)thiazole 6-iodoimidazo[1,2-a]pyridine-3-carbonitrile 2-(4-chlorophenyl)-2-morpholinoacetonitrile 4-chloro-7H-pyrrolo[2,3-d]pyrimidine 4-chloroisothiazole 5-bromo-6-chloro-1H-indole 7-chloro-3H-imidazo[4,5-b]pyridine ethyl3-(4-formylphenyl)propanoate 2,3-dibromobenzaldehyde 1-(5H-chromeno[2,3-b]pyridin-7-yl)ethanone 5H-chromeno[2,3-b]pyridin-5-one 3-chloroisoquinoline-4-carbaldehyde (E)-2-(3-oxoprop-1-enyl)benzaldehyde methyl4-formyl-3-nitrobenzoate 5,6-dimethoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-one 1-methylbicyclo[4.1.0]heptan-3-one 3-nitro-4-(trifluoromethoxy)benzaldehyde 2-hydroxyquinoline-6-carbaldehyde 2-nitro-3-(trifluoromethyl)benzaldehyde 1-(2-fluoro-4-methoxyphenyl)propan-2-one tert-butyl3-fluoro-4-oxopiperidine-1-carboxylate tert-butyl3-oxopropylcarbamate 2,2-dimethylcyclohexanone 9H-carbazole-3-carbaldehyde N,N-dimethyl-2-oxoacetamide 2-methylpent-4-yn-2-ol 3-tert-butyl-4-hydroxybenzonitrile 4-bromo-2-tert-butylphenol 1,3-dibutoxypropan-2-ol methyl4-hydroxyquinoline-6-carboxylate methyl3-cyano-4-hydroxybenzoate 4-chloro-6-methoxyquinolin-7-ol 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol 2-(2-aminothiazol-5-yl)ethanolhydrochloride (R)-ethyl2-chloropropanoate (S)-4-amino-5-(4,4-dimethylcyclohexylamino)-5-oxopentanoicacid (1s,4s)-4-hydroxycyclohexanecarboxylicacid (S)-2-(tetrahydrofuran-3-yloxy)aceticacid (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol (R)-4-(hydroxymethyl)oxazolidin-2-one (S)-4-(hydroxymethyl)oxazolidin-2-one 化工資訊 為進一步強化藥品生產(chǎn)源頭監(jiān)管，日前，菏澤市食品藥品監(jiān)督管理局約談11家中成藥生產(chǎn)企業(yè)和9家中藥飲片生產(chǎn)企業(yè)負責人、質(zhì)量受權人，進一步規(guī)范企業(yè)的生產(chǎn)和質(zhì)量管理行為。
會議通報了國家食品藥品監(jiān)督管理總局、省食品藥品監(jiān)督管理局藥品生產(chǎn)企業(yè)飛行檢查情況和中藥生產(chǎn)企業(yè)檢驗能力評估結果，并緊密結合當前監(jiān)管形式，指出了當前全市中藥企業(yè)存在的質(zhì)量風險和隱患。
要求中藥生產(chǎn)企業(yè)要提高企業(yè)第一責任人意識，不斷建立和完善質(zhì)量監(jiān)控體系，保證原料供應等全部環(huán)節(jié)處于受控狀態(tài)；要求嚴把藥材和原輔料進廠關，嚴格供應商審計，加強驗收和檢驗，確保原輔料質(zhì)量；嚴格成品檢驗和放行管理，成品必須按照國家藥品標準或者省炮制規(guī)范進行選項檢驗合格后，才能放行銷售；加快新修訂GMP實施進度，務必在2015年上半年全部通過新修訂GMP現(xiàn)場檢查。
